SAN DIEGO, July 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN - News) today reported financial results for the quarter ended June 30, 2009. The Company reported total revenue of $209.4 million for the quarter ended June 30, 2009, which includes net product sales of $197.5 million. Net loss, excluding a charge of $11.4 million associated with the Company’s sales force reduction in the second quarter, was $51.0 million, or $0.36 per share. Non-GAAP operating loss was $22.4 million for the quarter ended June 30, 2009, compared to $40.3 million for the same period in 2008. GAAP net loss was $62.4 million, or $0.44 per share, for the quarter ended June 30, 2009, compared to $66.6 million, or $0.49 per share, for the same period in 2008. At June 30, 2009 the Company held cash, cash equivalents and short-term investments of $644.4 million.
